Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07879755
Recruiting Not applicable

An Extension Trial of GW 906 in Participants With Essential Hypertension

NCT07879755 · tracked via the Priya Life Science China tracker
Sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd
Phase
Not applicable
Started
2026-06-12
Last updated
2026-10-19

Condition(s) studied

Hypertension

Investigational drug(s) / intervention(s)

GW906 →

GW906: Subcutaneous injection. Expected to be up to 2 years

Study summary

This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Completed study treatment and the study in accordance with the protocol for GW906 injection. * Willing to participate in the study and provide written informed consent. Exclusion Criteria: * Secondary hypertension. * Orthostatic hypotension accompanied by hypotension-related symptoms was observed in a prior study of GW906 injection. * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5× upper limit of normal (ULN); Total bilirubin \> 1.5 × ULN; International normalized ratio (INR) \> 2.0; Serum potassium \> 5.0 mmol/L or \< 3.5 mmol/L; eGFR≤30 mL/min/1.73m\^2. * History of any cardiovascular event within 6 months. * Patients with active malignancy or a history of malignancy.

Primary outcome measure(s)

  • Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to treatment discontinuation — every 3 month, up to 3 years
    An adverse event (AE) is any untoward medical occurrence in a participant administered with investigational medicinal product, which may manifest as signs, symptoms, disease, or abnormal laboratory findings

Trial sites (1)

FacilityCityRegionStatus
Shanghai Jiao Tong University School of Medicine, Ruijin Hospital Shanghai Shanghai Municipality Recruiting

More Shenzhen Salubris Pharmaceuticals Co., Ltd. trials in China

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies Recruiting
A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD) Active, not recruiting
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism Starting soon
A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications Starting soon
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants Starting soon

Other trials for the same condition

Prospective National Multi-center Registry of Obstructive Sleep Apnea Syndrome in Hypertensive Patients in China Recruiting
A Cluster-Randomized Trial of a Hypertension Risk Model-Based Precision Intervention in High-Risk Adults in Shunyi District Recruiting
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism Recruiting
Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases Recruiting
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07879755 on ClinicalTrials.gov ↗ ← All trials in China